MIRA - LONG
Updated
Amid concerns about MIRA Pharmaceuticals' cash burn, there are compelling reasons for optimism. The company has smartly reduced its cash burn by 8.1% in the past year, extending its cash runway to about 16 months as of September 2023. This indicates prudent financial management and a strategic approach to growth.
The partnership with Pharmaseed Ltd. to develop Ketamir-2, a novel treatment for neurological and neuropsychiatric disorders, highlights MIRA's innovative edge. This venture into addressing major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) has significant market potential, with projections suggesting Ketamir could generate $3 billion in annual sales by 2035.
As we have established a very strong support here, and given the history of volatile moves, eyeing potential price target in the $1.50 range, low volume node. My bullish outlook is supported by MIRA's strategic initiatives, potential market impact, and solid financial strategy, making it an attractive option for investors seeking growth in a stock with considerable upside.
Trade closed: target reached
Taking off the table here, Target reached.Mira Pharmaceuticals (NASDAQ:MIRA) saw its stock surge by 51.7% on Friday following an exciting preclinical trial update. The company discovered a new molecule, named MIRA-55, during the testing of its oral pharmaceutical marijuana drug candidate, MIRA1a. An unexpected error in MIRA1a's production led to the creation of MIRA-55, which preclinical trials have shown to be more potent and potentially more efficacious. Consequently, Mira Pharmaceuticals has decided to prioritize the development of MIRA-55 while maintaining its rights to MIRA1a. This shift in focus has garnered significant investor interest, resulting in a substantial increase in MIRA stock's trading volume to over 6 million shares, compared to its daily average of around 232,000 shares. This development highlights the company's potential for breakthrough in its drug development efforts, making it a standout moment for investors and the pharmaceutical sector.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.